NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Nuvation Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Market Cap | $1.57B | $197.05M |
| Enterprise Value | $917.97M | $106.56M |
| PS Ratio | 9.26 | 3.93 |
| PB Ratio | 6.20 | 2.14 |
| P/TBV Ratio | 6.46 | 2.46 |
Enterprise value
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| EV / Sales | 5.40 | 2.69 |
Income (trailing twelve months)
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Revenue | $169.90M | $57.94M |
| Operating Income | -$137.63M | -$21.44M |
| Pretax Income | -$149.83M | -$14.45M |
| Net Income | -$149.83M | -$22.46M |
| EBITDA | -$135.48M | -$16.91M |
Margins
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Operating Margin | -81.0% | -44.5% |
| Pretax Margin | -88.2% | -13.0% |
| Profit Margin | -88.2% | -39.2% |
| EBITDA Margin | -79.7% | -31.3% |
Returns
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -47.8% | -53.1% |
| Return on Assets (ROA) | -21.5% | -41.0% |
| Return on Capital Employed (ROCE) | -20.9% | -37.8% |
Growth
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1083.6% | 6.01% |
Balance sheet
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $660.96M | $62.42M |
| Total Debt | $5.89M | $120.13M |
| Net Cash (Debt) | $655.06M | $15.68M |
| Net Cash Per Share | $1.87 | $0.65 |
| Equity (Book Value) | $253.86M | $48.79M |
| Book Value Per Share | $0.72 | $1.36 |
| Tangible Book Value | $243.57M | $23.06M |
| Working Capital | $639.68M | $75.77M |
Financial position
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Current Ratio | 8.37 | 3.30 |
| Quick Ratio | 7.94 | 2.39 |
| Debt / Equity | 0.02 | 0.51 |
| Interest Coverage | -5.45 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$120.52M | -$12.35M |
Efficiency
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.24 | 0.38 |
| Revenue Per Employee | $570.13K | $398.96K |
| Profits Per Employee | -$502.78K | -$732.08K |
| Employee Count | 298 | 73 |
Dividends and yields
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Earnings Yield | -9.52% | -21.2% |
Shares
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Shares Outstanding | 351,123,000 | 59,128,900 |
| Shares Change (YoY) | 9.51% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 258,522,000 | 48,744,500 |
| Shares Held by Insiders | 26.4% | 11.8% |
| Shares Held by Institutions | 66.5% | 59.4% |
Taxes
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Nuvation Bio | Industry median |
|---|---|---|
| Altman Z-Score | 0.37 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Nuvation Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.